Buying stocks with a low forward Price-to-Earnings (P/E) ratio is a classic value-investing approach centered on identifying companies that may be undervalued relative to their expected future earnings. Because the forward P/E reflects projected profits rather than historical results, it serves as a more forward-looking metric, helping investors pinpoint opportunities where the market may be underestimating growth or pricing in overly pessimistic expectations. In essence, a low forward P/E allows investors to pay less today for tomorrow’s earnings—a dynamic that can create favorable risk-reward setups.

The appeal becomes even stronger when these “cheap” stocks also carry “Strong Buy” ratings from analysts. A strong buy rating typically reflects high conviction among analysts that a stock is likely to outperform, based on factors such as earnings visibility, improving fundamentals, or favorable industry trends. When a stock combines a low forward P/E with a strong buy consensus, it suggests a powerful alignment: the company is both undervalued and positively viewed by informed market participants. This can indicate that the market has not yet fully priced in expected improvements, creating potential for both earnings-driven gains and valuation re-rating.

Low forward P/E stocks also offer several structural advantages. They can signal undervaluation relative to peers, highlight anticipated earnings growth (particularly when forward multiples are below trailing ones), and provide a margin of safety against downside risk. Unlike high-multiple growth stocks, which can experience sharp corrections if expectations are missed, lower-valued companies often have more modest expectations baked into their prices. Many are also mature, cash-generative businesses capable of returning capital through dividends while still offering incremental growth.

This philosophy aligns closely with the thinking of some of the world’s most successful investors. Warren Buffett famously said, “Price is what you pay; value is what you get,” emphasizing the importance of buying quality businesses at reasonable valuations. Similarly, Benjamin Graham, often regarded as the father of value investing, advocated for purchasing stocks with a margin of safety—buying below intrinsic value to protect against uncertainty. More recently, Howard Marks has stressed that superior investing is about buying assets “for less than they’re worth,” particularly when market sentiment is overly negative.

When strong analyst conviction meets discounted valuation, investors gain a compelling combination: credible upside potential supported by both fundamentals and expert endorsement. Over time, as earnings materialize and sentiment improves, these stocks can deliver meaningful outperformance, making them particularly attractive for disciplined, long-term investors.

With this context in mind, here is a list of 13 cheapest strong buy stocks to buy right now.

Our Methodology

For this list, we screened for stocks with positive analyst sentiment and identified stocks with consensus Strong Buy ratings that are trading below a forward P/E of 15. We limited our final selection to companies that have recently reported noteworthy developments that are likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

13 Cheapest Strong Buy Stocks to Buy Right Now

13. Bank of America Corporation (NYSE:BAC)

On April 1, HSBC analyst Saul Martinez upgraded Bank of America Corporation (NYSE:BAC) to Buy from Hold with a price target of $55, reduced from $57, citing a shift in market dynamics that has repriced downside macroeconomic risks and renewed credit concerns across U.S. bank stocks. The analyst noted that the multi-year return on equity expansion narrative for universal banks is now less fully reflected in current valuations, creating a more attractive entry point for investors. As a result, HSBC sees Bank of America as well-positioned to benefit from a re-rating as market sentiment stabilizes.

A day earlier, Morgan Stanley lowered its price target on Bank of America Corporation (NYSE:BAC) to $61 from $67 while maintaining an Overweight rating, reflecting broader sector pressure rather than company-specific weakness. The firm highlighted that bank stocks have declined approximately 5% over the past month amid concerns surrounding geopolitical tensions in the Middle East, inflation risks, and uncertainty in private credit markets. Despite these headwinds and a reduction in valuation multiples across the group, the continued Overweight rating signals confidence in Bank of America’s underlying fundamentals and earnings resilience.

Bank of America Corporation (NYSE:BAC) is a leading global financial institution offering a comprehensive suite of banking, investment, and risk management services. Headquartered in Charlotte, North Carolina, the company benefits from a diversified business model and significant scale across consumer and institutional segments. With valuation multiples compressed due to macro uncertainty and continued support from analysts, Bank of America presents an attractive opportunity for investors seeking exposure to a high-quality financial franchise with meaningful upside potential as economic conditions stabilize.

12. The Walt Disney Company (NYSE:DIS)

On April 1, Raymond James upgraded The Walt Disney Company (NYSE:DIS) to Outperform from Market Perform with a $115 price target, citing an increasingly compelling valuation backdrop. The firm noted that macroeconomic pressures and international visitation headwinds have weighed on sentiment, creating an opportunity to invest at historically attractive levels. Despite stress-testing more conservative scenarios, the analyst emphasized that Disney’s shares remain undervalued, with its streaming segment expected to drive the majority of future operating income growth, supporting a favorable risk-reward profile.

On March 30, The Walt Disney Company (NYSE:DIS) announced a partnership with Comixit!, a platform founded by Envision Entertainment CEO Michael Nakan, aimed at expanding webtoon distribution across the EMEA region. This initiative reflects Disney’s ongoing efforts to diversify its content ecosystem and tap into rapidly growing digital storytelling formats, particularly among younger, global audiences, thereby strengthening its long-term content monetization strategy.

The Walt Disney Company (NYSE:DIS) is a global entertainment leader headquartered in Burbank, California, with operations spanning film and television production, streaming platforms, theme parks and resorts, and consumer products. With a robust portfolio of iconic brands including Disney, Pixar, Marvel, and Lucasfilm, the company is well-positioned to capitalize on evolving media consumption trends. Supported by improving streaming economics and strategic content expansion, Disney offers a compelling investment opportunity with significant upside as valuation multiples normalize and growth initiatives gain traction.

]]> https://www.insidermonkey.com/blog/5-cheapest-strong-buy-stocks-to-buy-right-now-1732440/ Mon, 06 Apr 2026 21:43:05 +0000 https://www.insidermonkey.com/blog/?p=1732440 In this article, we will discuss the 5 Cheapest Strong Buy Stocks to Buy Right Now. For deeper discussion and analysis, read 13 Cheapest Strong Buy Stocks to Buy Right Now.

5. Delta Air Lines, Inc. (NYSE:DAL)

On April 2, TD Cowen lowered its price target on Delta Air Lines, Inc. (NYSE:DAL) to $76 from $77 while maintaining a Buy rating, as part of a broader reassessment of the airline sector ahead of first-quarter earnings. The firm cited investor concerns regarding the durability of travel demand amid rising energy costs and weakening credit card spending data. Despite these headwinds, Delta is viewed as the most defensive name within the sector, reflecting its strong operational execution and premium positioning.

On March 30, industry reports indicated that airlines have begun raising fares and reducing capacity to offset the impact of surging oil prices, which have significantly increased fuel costs. While the industry had previously projected record profits of $41 billion in 2026, the sharp rise in jet fuel prices has introduced uncertainty and forced carriers such as Delta Air Lines, Inc. (NYSE:DAL) to adjust their strategies. The extent to which profitability is maintained will depend on consumer resilience in the face of higher travel costs.

Delta Air Lines, Inc. (NYSE:DAL) is a major global airline providing passenger and cargo transportation services, supported by a comprehensive network and operational scale. The company also offers maintenance, repair, and overhaul services, contributing to diversified revenue streams. With a strong brand, disciplined capacity management, and positioning as a premium carrier, Delta is better equipped than its peers to navigate industry volatility, supporting a favorable long-term investment outlook with meaningful upside potential.

]]> https://www.insidermonkey.com/blog/cytomx-therapeutics-inc-ctmx-making-progress-on-key-metastatic-colorectal-cancer-treatment-1732865/ Mon, 06 Apr 2026 21:25:50 +0000 https://www.insidermonkey.com/blog/?p=1732865 CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the best multibagger penny stocks to invest in. On March 23, analysts at Piper Sandler reiterated an Overweight rating on CytomX Therapeutics, Inc. (NASDAQ:CTMX) and increased the price target to $12 from $10.

The price target hike comes against the backdrop of topline Phase 1 data on varsetatug maseatecan in third-line and later metastatic colorectal cancer. Clinical trial results showed that the candidate drug achieved a 32% objective response rate and an 84% disease control rate.

The positive Phase 1 data reinforce Varseta-M’s potential as a standard of care for the treatment of colorectal cancer. CytomX is to engage the FDA to discuss the initial registration path for bringing this highly innovative, first-in-class ADC to the market.

The company has also initiated a Phase Ib study of Varseta-M combined with Avastin, as it also plans to start a Phase Ib/II trial that combines Avastin with chemotherapy in earlier-line colorectal cancer.

CytomX Therapeutics also plans to present Phase I data on CX-801 combined with KEYTRUDA in advanced melanoma patients by the end of the year. It has priced a $250 million public offering of its common stock at $5.30. The company plans to use the net proceeds from the offering to accelerate its drug development efforts.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics, which are masked, conditionally activated antibody treatments designed to target tumor microenvironments. This technology aims to improve cancer treatment safety and efficacy by localizing drug activity within tumors, reducing toxicity in healthy tissues.

[im-yf-promo]

While we acknowledge the potential of CTMX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: Motley Fool’s 10 High-Growth Stock Picks and 8 Best Blue Chip AI Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.

Pressmaster/Shutterstock.com

The positive stance is in response to the company making significant progress on the development of TSHA-102, an investigational gene transfer therapy in evaluation for Rett syndrome. Chief Executive Officer Sean Noland has already confirmed they are bolstering commercial-readiness efforts ahead of potential registration.

Taysha Gene Therapies has also received FDA clearance to initiate the ASPIRE trial in 3 patients to support a potential broad label in the second quarter. The milestone follows a favorable tolerability profile, continued patient enrollment, and a well-defined regulatory trajectory.

Amid TSHA-102 development progress, Taysha Gene Therapies reported a net loss of $109 million, or $0.34 per share, for the year ended December 31, 2025. It was a significant increase from a net loss of $89.3 million, or $0.36 a share, for the year ended 2024. The wider-than-expected net loss was due to an increase in research and development expenses, which came in at $86.4 million, up from $66 million in 2024.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for severe monogenic central nervous system diseases. Their lead candidate, TSHA-102, uses miRNA-regulatory technology to treat Rett syndrome, aiming to address the disease’s underlying genetic cause.

[im-yf-promo]

While we acknowledge the potential of TSHA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: Motley Fool’s 10 High-Growth Stock Picks and 8 Best Blue Chip AI Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.

The price target hike underscores the research firm’s confidence in the company’s lead drug, PAPZIMEOS, as a frontline standard of care for recurrent respiratory papillomatosis. The drug received full FDA approval last year as the first immunotherapy for recurrent respiratory papillomatosis. Management has already indicated that they are on course to generate more than $18 million in PAPZIMEOS sales in the first quarter.

Citizen’s is confident sales will exceed guidance, given solid commercial metrics, including patient engagement and enrollment in hubs. Engaged patient profiles for papillomatosis are broad, including patients who have undergone many surgeries. The company remains well-positioned to capitalize on PAPZIMEOS edge as the first and only approved therapy for recurrent respiratory papillomatosis.

Precigen, Inc. (NASDAQ:PGEN) is a clinical-stage biopharmaceutical company focused on developing next-generation gene and cell therapies, specifically in immuno-oncology, autoimmune disorders, and infectious diseases.

[im-yf-promo]

While we acknowledge the potential of PGEN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: Motley Fool’s 10 High-Growth Stock Picks and 8 Best Blue Chip AI Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.

The company has successfully integrated the solution across partners to collectively represent 90% of the advertising ecosystem. With the integration, the company has asserted its position as a reliable layer for sports advertising while connecting live sports data across the digital media ecosystem.

Genius Sports has tailored Moment Engine to act on fan attention and automatically trigger campaigns when live action is most compelling. It has already been deployed during key sporting events, including the Super Bowl, where brands successfully triggered campaigns in real time.

Some of the key adopters include Publicis, Magnite, OpenX, PubMatic, FreeWheel, and DIRECTV. According to Benchmark, Genius Sports is well-positioned to capitalize on this, given that its current integrations account for 90% of the digital advertising ecosystem.

Genius Sports Limited (NYSE:GENI) is a global leader in sports data, technology, and broadcasting, acting as the official partner to over 700 sports organizations, including the NFL, EPL, and NBA. It captures real-time statistics, power sportsbooks’ live betting, delivers AI-driven video analytics, and provides fan engagement tools to leagues and media companies.

[im-yf-promo]

While we acknowledge the potential of GENI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: Motley Fool’s 10 High-Growth Stock Picks and 8 Best Blue Chip AI Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.

The European Medicines Agency has validated the company’s Marketing Authorization Application for the candidate treatment of advanced ROS1-positive non-small cell lung cancer. Consequently, the review of taletrectinib is expected to take 1 year. The research firm expects an uneventful approval process in the EU, based on the topline clinical trial data.

Nuvation Bio made the submission following positive pivotal Phase 2 TRUST-I and TRUST-II studies. Therefore, European Market authorization is to be supported by favorable feedback received at a permission meeting with the CHMP Rapporteur and Co-Rapporteur.

The company is on course to secure $30 million in milestone payments from partner Eisai on securing EU regulatory approval. The drug has already received full approval in the US from the Food and Drug Administration.

Nuvation Bio Inc. (NYSE:NUVB) is a commercial-stage global biopharmaceutical company, founded in 2018, focused on developing novel, targeted oncology therapies for difficult-to-treat cancers. In June 2025, they entered the commercial stage with the FDA approval of IBTROZI (taletrectinib), a next-generation inhibitor for ROS1-positive non-small cell lung cancer.

[im-yf-promo]

While we acknowledge the potential of NUVB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: Motley Fool’s 10 High-Growth Stock Picks and 8 Best Blue Chip AI Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.

Photo by Gold-bar-jingming-pan on Unsplash

The company achieved consolidated silver production of 2.65 million ounces, or approximately 3.4 million silver equivalent, and revenue in the year was up 18% to $118 million, driven by higher silver production and processing. Americas Gold and Silver realized a 39% increase in silver prices, offsetting 4.3% declines in lead and 0.8% in zinc.

However, Americas Gold and Silver Corporation plunged to a wider-than-expected adjusted loss of $35.2 million, or $0.13 a share, compared to an adjusted loss of $33.7 million, or $0.32 a share, in 2024. Adjusted EBITDA was a loss of $4.1 million, up from $1.5 million in 2024, due to increased operational spending as part of a strategic investment at Galena to enhance production.

Americas Gold and Silver Corporation (NYSEAMERICAN:USAS) is a North American precious metals mining company focused on exploring, operating, and developing high-grade silver, copper, and antimony projects. The company operates the Galena Complex in Idaho, USA, and the Cosalá Operations in Mexico, aiming to be a top-tier silver and antimony producer.

[im-yf-promo]

While we acknowledge the potential of USAS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: Motley Fool’s 10 High-Growth Stock Picks and 8 Best Blue Chip AI Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.

Photo by Pietro Jeng on Pexels

The expanded partnership also underscores the company’s commitment to building a more predictive and patient-centered biopharmaceutical ecosystem. It also follows the integration of Citeline’s SmartSolutions into the Recursion platform to provide data access during early development stages.

The expanded partnership paves the way for integrating Citeline’s real-world data and evidence capabilities into Recursion’s end-to-end platform. The integration will strengthen the platform’s foundation, enabling more precise trial design, improved site selection, and informed development decisions.

The addition of Citeline’s data and evidence capabilities to the company’s robust platform is also poised to support pipeline development. The ClinTech platform is already yielding results, including 30%-60% improvements in enrollment, affirming the importance of integration.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is a clinical-stage “TechBio” company that uses artificial intelligence (AI), machine learning, automation, and high-throughput biology to enhance drug discovery and development.

[im-yf-promo]

While we acknowledge the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: Motley Fool’s 10 High-Growth Stock Picks and 8 Best Blue Chip AI Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.

As macroeconomic uncertainty builds in 2026, investors are increasingly re-evaluating where to find resilient and opportunistic returns. Strategists at Bank of America have pointed to rising stagflation risks and higher market volatility, with the CBOE Volatility Index frequently moving above the key threshold of 20—an indication of growing investor anxiety. In such environments, historical data suggests that value-oriented strategies tend to outperform, particularly those focused on high-quality companies and businesses returning cash to shareholders. Notably, even as broader indices like the S&P 500 have faced pressure, value stocks have shown relative strength, reinforcing a shift away from expensive large-cap growth names.

Within this context, “cheap” stocks, which are often defined by low forward price-to-earnings (P/E) ratios, are attracting renewed attention. Because forward P/E ratios are based on expected future earnings rather than past performance, they provide a more relevant lens for identifying undervalued opportunities in a forward-looking market. With the S&P 500 still trading above its long-term average multiple, the margin for error in expensive stocks remains limited, further strengthening the case for disciplined, value-focused investing.

An increasingly compelling subset of this opportunity lies in penny stocks that also trade at low forward P/E ratios. While penny stocks are often associated with higher risk, combining low share prices with attractive forward valuations can uncover “diamonds in the rough”: companies where the market may be underestimating earnings potential or overlooking improving fundamentals. This approach aligns with how sophisticated investors operate. Figures like Ken Griffin and Steve Cohen have demonstrated a willingness to explore smaller, underfollowed companies with tangible assets, clear paths to profitability, or strong industry positioning rather than simply chasing low prices.

Importantly, penny stocks with low forward P/E ratios offer a unique asymmetric setup. Investors gain exposure to potentially significant percentage upside due to the low entry price, while the earnings-based valuation provides a layer of fundamental support often missing in purely speculative plays. When combined with indicators such as insider buying or increasing institutional interest, these stocks can transition from overlooked to re-rated, delivering outsized returns. In a market defined by volatility and shifting leadership, selectively targeting fundamentally sound, low-priced value opportunities may offer one of the most compelling paths to long-term gains.

With this context in mind, here is a list of 12 cheap penny stocks to invest in now.

Our Methodology

We used screeners to identify stocks that are trading below a forward P/E of 15 for less than $5 a share, and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

12 Cheap Penny Stocks to Invest In Now

12. Wipro Limited (NYSE:WIT)

On March 17, Wipro Limited (NYSE:WIT) and Harness announced a strategic collaboration aimed at enabling global enterprises to accelerate AI-native software delivery with enhanced efficiency, reliability, and governance. Management highlighted that the continued evolution of Wipro’s WEGA agent-based delivery platform is designed to help clients unlock faster time-to-value, build more intelligent systems, and scale AI initiatives with greater confidence. This partnership establishes a framework for AI-first software development, reinforcing Wipro’s positioning in next-generation digital transformation and strengthening its ability to capture enterprise AI spending.

On March 5, 2026, the company’s board approved the appointment of Laura Marie Miller as an independent director for a five-year term beginning April 1, 2026, subject to shareholder approval. Wipro Limited (NYSE:WIT) confirmed that she meets all regulatory independence criteria and has no affiliations with existing board members. Miller brings extensive leadership experience in digital transformation, having held senior roles such as EVP and Chief Information and Data Officer at Macy’s, along with board positions at NCR Voyix and Ahold Delhaize. Her appointment enhances Wipro’s governance framework and adds deep expertise in data and AI strategy, signaling a continued emphasis on innovation-led growth and disciplined oversight.

Wipro Limited (NYSE:WIT) is a global leader in information technology services, consulting, and business process outsourcing, headquartered in Bengaluru, India. Originally founded in 1945 as a consumer goods company, it transitioned into IT services in 1980 and has since evolved into a major player in digital transformation, making it a relevant beneficiary of rising enterprise demand for AI-driven solutions.

11. UWM Holdings Corporation (NYSE:UWMC)

On March 28, UWM Holdings Corporation (NYSE:UWMC) issued a statement regarding its proposal to acquire TWO, criticizing the target’s management and board for actions it believes are not aligned with shareholder interests. The company emphasized that its strategic intent was focused on acquiring servicing assets rather than operational integration, noting that its own platform is already highly efficient. UWMC also highlighted its growth trajectory in contrast to what it described as structural challenges within TWO’s business, reinforcing its confidence in maintaining leadership within the wholesale mortgage channel.

For its Q4 2025 results, UWM Holdings Corporation (NYSE:UWMC) reported total quarterly revenue of $945 million, up from $843 million in Q3, and full-year revenue of $3.2 billion, representing approximately 18.5% growth year over year. Adjusted EBITDA exceeded $697 million for the year, including $232.8 million in Q4, while net income rose sharply to $164.5 million from $12.1 million in the prior quarter. This significant improvement reflects strong operating leverage and execution, supporting the company’s positioning as a scalable growth platform within the mortgage industry.

UWM Holdings Corporation (NYSE:UWMC) is a leading U.S. residential mortgage lender and the parent company of United Wholesale Mortgage, the largest wholesale mortgage originator in the country. Founded in 1986 and headquartered in Pontiac, Michigan, the company’s scale, efficiency, and growth momentum position it as a compelling opportunity in a recovering housing finance market.

]]> https://www.insidermonkey.com/blog/5-cheap-penny-stocks-to-invest-in-now-1732280/ Mon, 06 Apr 2026 21:19:15 +0000 https://www.insidermonkey.com/blog/?p=1732280 In this article, we will discuss the 5 Cheap Penny Stocks to Invest In Now. For deeper discussion and analysis, read 12 Cheap Penny Stocks to Invest In Now.

5. AlTi Global, Inc. (NASDAQ:ALTI)

On March 31, AlTi Global, Inc. (NASDAQ:ALTI) reported fourth-quarter EPS of $(0.20), a notable improvement from $(0.55) in the prior-year period, alongside revenue of $88.3 million compared to $51.5 million last year. The significant year-over-year revenue expansion, coupled with a marked narrowing of losses, underscores strengthening operating momentum and suggests that the firm is beginning to realize scale benefits following its recent strategic combination, reinforcing the potential for continued earnings normalization and value creation.

On the same day, AlTi Global, Inc. (NASDAQ:ALTI) announced the appointment of Nancy Curtin as Interim Chief Executive Officer and a member of its Board of Directors, effective immediately. Curtin, who has served as Global Chief Investment Officer since the firm’s formation, succeeds Michael Tiedemann, who will remain in an advisory role to support a smooth leadership transition. The appointment of an experienced internal executive with deep investment expertise provides continuity in strategic direction and reinforces confidence in the firm’s ability to execute on its long-term growth initiatives.

AlTi Global, Inc. (NASDAQ:ALTI) is a leading independent global wealth and asset manager formed in January 2023 through the combination of Tiedemann Wealth Management, Alvarium Investments, and Cartesian Growth Corporation. Headquartered in New York, the firm serves ultra-high-net-worth individuals, families, and institutions through a comprehensive platform spanning wealth management, alternative investments, and fiduciary services. With improving financial performance, leadership stability, and increasing scale, AlTi is well-positioned to capitalize on growing demand for sophisticated wealth solutions, supporting a compelling investment case with meaningful upside potential.

]]> https://www.insidermonkey.com/blog/heres-why-warren-buffett-and-ken-griffin-love-apple-aapl-1732037/ Mon, 06 Apr 2026 21:19:03 +0000 https://www.insidermonkey.com/blog/?p=1732037 We just covered the 10 Best Stocks to Buy According to Billionaire Ken Griffin. Apple (NASDAQ:AAPL) ranks #5 (see the 5 Best Stocks to Buy According to Ken Griffin).

Ken Griffin’s Stake Value: $1,500,827,597

Apple is gaining favor on Wall Street after previously being dismissed as an AI laggard. The biggest vote of confidence recently came from Warren Buffett, who openly said in a CNBC interview that he sold Apple shares “too soon.” Apple remains Berkshire Hathaway’s largest holding.

“Well, I sold it too soon,” Buffett recently said. “But I bought it even sooner. So, it worked.”

Two factors had been weighing on Apple’s stock: first, declining iPhone sales, which remain its bread and butter; and second, the lack of a clear AI strategy.

Wall Street was extremely skeptical of Apple’s (NASDAQ:AAPL) AI strategy until concerns over increasing data center spending and ROI started popping holes in the AI hype, making the Cupertino giant’s approach look increasingly prudent. Apple (NASDAQ:AAPL) spent just about $12.7 billion in CapEx last year, while major tech companies like Microsoft, Google, Meta and Amazon are expected to spend about $600 billion combined on AI infrastructure in 2026.

What about the concerns about declining iPhone sales? Earlier this year, Apple (NASDAQ:AAPL) issued a higher-than-expected revenue growth guidance for the March quarter driven by a rebound in iPhone demand. But let’s face it: Analysts are now coming to terms with the reality that iPhone sales are unlikely to keep delivering strong growth as users may not upgrade as frequently.

Apple (NASDAQ:AAPL) anticipated this shift and began diversifying into services and other higher-margin business segments. As of the fiscal Q1, Apple’s Services revenue reached an all-time record of $30 billion, accounting for about 21% of total revenue. Services gross margins are about 76%,  nearly double the 40.7% margin seen on physical products. With an installed base of 2.5 billion devices, Apple (NASDAQ:AAPL) is positioned well to keep making money despite a potential plateau in iPhone sales.

Apple ranks fifth in our list of the best stocks to buy according to billionaire Ken Griffin.

RiverPark Large Growth Fund explained in its investor why Apple remains among the world’s most resilient and profitable businesses. Click here to read the full text of the letter.

[im-yf-promo]

While we acknowledge the potential of AAPL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

The research firm updated its model for the company to reflect current strip pricing. A few days prior, on March 25, UBS also increased its price target on Venture Global, Inc. (NYSE:VG) from $19 to $21 while keeping a Buy rating on the stock. These updates come after the company reported record-breaking performance for Q4 2025. Venture Global, Inc. (NYSE:VG) exported 128 cargos and sold 478 trillion British thermal units (TBtu) of liquified natural gas (LNG), which is a new record for the company and an increase of 95 cargos and 351 TBtu sold, or 275%, compared to Q4 2024. The company’s revenue also surged to $4.4 billion, up 192% year-over-year, while income from operations climbed to $1.7 billion, up 189% year-over-year.

Venture Global’s Plaquesmine facility. Photo from Venture Global website

Another firm optimistic on VG is RBC Capital. On March 13, RBC Capital lifted its price target on Venture Global, Inc. (NYSE:VG) from $11 to $14 and maintained an Outperform rating on the stock. The research firm revised its estimates after the company reported Q4 2025 results.

RBC pointed out that about 31% of Venture Global, Inc.’s (NYSE:VG) cargoes remain unsold. The firm said that the company can “benefit from higher global LNG prices given ~31% of 2026 cargoes are unsold, and could drive results above guidance and our estimates if able to lock in higher rates.”

Venture Global, Inc. (NYSE:VG) is an American company that produces and exports liquefied natural gas (LNG).

[im-yf-promo]

While we acknowledge the potential of VG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 10 Best Car Stocks to Buy in 2026 and 10 Best AI Stocks to Buy for the Next 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.

The research firm said the company provided strong guidance for the first quarter along with a solid outlook for 2026, which suggests revenue growth of 15% to 20%. Although the fourth quarter of 2025 was mixed, Oppenheimer believes that it is backward-looking as James Xiao, the new CEO, rolls out the “UCT 3.0” plan during a solid market cycle and possibly an AI- and memory-driven “ultra” cycle.

On the same day, Needham also increased its price target on Ultra Clean Holdings, Inc. (NASDAQ:UCTT) from $50 to $70 and kept a Buy rating on the stock after the company’s Q4 results.

Needham pointed out that customer forecasts for 2026 are improving on a weekly basis. The firm also expects to see wafer fabrication equipment (WFE) growth of 15% to 20% in 2026, with a stronger increase in the third quarter.

Ultra Clean Holdings, Inc. (NASDAQ:UCTT) is a leading developer and supplier of critical subsystems, components, parts, and ultra-high purity cleaning and analytical services, primarily serving the semiconductor industry.

[im-yf-promo]

While we acknowledge the potential of UCTT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 10 Best Car Stocks to Buy in 2026 and 10 Best AI Stocks to Buy for the Next 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.

As of the latest close on April 2, 2026, the stock was down about 36.2% year to date, based on a $10.63 close on January 2 and a $6.78 close on April 2.

The latest company-specific development came on April 2, when SoundHound AI said Quálitas, a major auto insurer in Mexico, expanded its use of the company’s AI agent platform from contact-center work into end-to-end claims resolution. According to the release, the broader rollout followed earlier success in customer service, where AI-handled call volume rose 150%.

Source: unsplash

SoundHound said its agentic AI now manages more than 74% of Quálitas’ car-assistance requests end to end and captures policy numbers in more than 80% of interactions. The company said that has helped reduce human escalations while speeding up claims-related workflows. The announcement suggests SoundHound is still pushing beyond voice interfaces into more operational, enterprise-style AI deployments, particularly in insurance.

SoundHound AI, Inc. (NASDAQ:SOUN) provides voice, conversational, and agentic AI technologies for businesses across industries including automotive, restaurants, telecom, and customer service.

[im-yf-promo]

While we acknowledge the potential of SOUN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.

On March 26, Klein said in a note that the strong rally seen throughout 2025 and early 2026 is now losing some momentum and the “memory long trade [is] starting to wobble big time.”

However, Klein pointed out that such violent cycles are not unusual in the memory sector and the recent pullback fits a familiar pattern. He noted that “these sell-offs happen every few months… Not a signal of peak nor any reason to dump. Actually you make money buying these dips.” Klein is positive on memory stocks and said he sees upside for Sandisk Corporation (NASDAQ:SNDK).

Also on March 26, Morgan Stanley reaffirmed its Overweight rating on Sandisk Corporation (NASDAQ:SNDK). The research firm noted that the recent drop in memory stocks is linked to factors like capital spending, demand slowdown, and productivity. Despite these worries, Morgan Stanley believes the strength in the memory stocks is more durable than the market currently expects.

Sandisk Corporation (NASDAQ:SNDK) is an American computer technology company that designs and manufactures flash solutions and advanced memory technologies, including SSDs, memory cards, and USB Flash Drives.

[im-yf-promo]

While we acknowledge the potential of SNDK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 10 Best Car Stocks to Buy in 2026 and 10 Best AI Stocks to Buy for the Next 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.

The firm pointed to recent progress in PRMT5 inhibitors and RAS(ON) combinations, which the firm believes lowers the risk for the company’s first-line pancreatic ductal adenocarcinoma opportunity. Stifel also included risk-adjusted first-line pancreatic ductal adenocarcinoma credit into its financial model for Tango Therapeutics, Inc. (NASDAQ:TNGX).

Earlier, on March 5, Jefferies also increased its price target on Tango Therapeutics, Inc. (NASDAQ:TNGX) from $14 to $18 and maintained its Buy rating on the stock.

Jefferies pointed to the company’s supply agreement with ERAS for pan-RAS. The research firm pointed out that upcoming topline data from Revolution Medicines on daraxonrasib, expected in the first half of 2026 for second-line pancreatic ductal adenocarcinoma, could set a new standard of care.

Tango Therapeutics, Inc. (NASDAQ:TNGX) is a clinical-stage biotechnology company focused on the discovery of novel drug targets and the delivery of precision medicine for the treatment of cancer.

[im-yf-promo]

While we acknowledge the potential of TNGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 10 Best Car Stocks to Buy in 2026 and 10 Best AI Stocks to Buy for the Next 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.

Raymond James pointed out that full Phase 3 data was presented for both the company’s envu and competitor Takeda Pharmaceutical Company Limited’s (NYSE:TAK) zasocitinib in adults with moderate to severe plaque psoriasis.

The research firm noted that there is meaningful differentiation in safety profiles between the two drugs. Zasocitinib showed higher rates of treatment-emergent adverse events, serious adverse events and acne. It also had about twice the rate of upper respiratory tract infections and diarrhea compared to Alumis Inc.’s (NASDAQ:ALMS) envu. Raymond James believes envu emerged with a strong advantage over zasocitinib.

On the same day, Guggenheim also reiterated its Buy rating on Alumis Inc. (NASDAQ:ALMS) with a price target of $32 on the stock after the company’s Phase 3 psoriasis trials presented at the 2026 American Academy of Dermatology Annual Meeting.

Alumis Inc. (NASDAQ:ALMS) is a late-stage biopharma company focused on leveraging its proprietary data analytics platform and precision approach and developing next-generation targeted therapies for a range of immune-mediated diseases.

[im-yf-promo]

While we acknowledge the potential of ALMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 10 Best Car Stocks to Buy in 2026 and 10 Best AI Stocks to Buy for the Next 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.

This increase in valuation came after Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement under which it will acquire Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Enliven Therapeutics, Inc.’s (NASDAQ:ELVN) competitor, through a subsidiary for approximately $6.7 billion.

Earlier, on March 24, Mizuho also lifted its price target on Enliven Therapeutics, Inc. (NASDAQ:ELVN) from $41 to $45 and maintained its Outperform rating on the stock.

The research firm pointed to recent Phase 1b data for ELVN-001 as the key factor for this increase in the price target. Mizuho sees Enliven Therapeutics, Inc. (NASDAQ:ELVN) as an under-rated asset in the chronic myeloid leukemia market. The firm added that it expects more data from ELVN-001’s Phase 1a/b trial in mid-year.

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for cancer treatment.

[im-yf-promo]

While we acknowledge the potential of ELVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 10 Best Car Stocks to Buy in 2026 and 10 Best AI Stocks to Buy for the Next 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.

Supported by a revamped go-to-market strategy and a focus on high-performance edge solutions, the company achieved record gross margins and steady profitability in 2025. Fastly, Inc. (NASDAQ:FSLY) reported gross margins of 64% and said it was profitable throughout 2025. It also generated positive free cash flow in all of 2025. In the fourth quarter of 2025, revenue growth re-accelerated to 23%, supported by its security, compute, and observability businesses.

Looking ahead, the company aims to raise its remaining performance obligation (RPO) commitments to about 70% to 80% of revenue. Fastly, Inc. (NASDAQ:FSLY) also sees short-term monetization opportunities from AI traffic and is looking at security mechanisms to manage agentic traffic. Managing AI traffic is becoming a key focus, and the company is developing tools like Bot Mitigation.

Additionally, Fastly, Inc. (NASDAQ:FSLY) has more than $350 million in cash on its balance sheet and is open to strategic mergers and acquisitions.

Fastly, Inc. (NASDAQ:FSLY) operates a programmable, high-performance edge cloud platform that delivers faster, safer, and more scalable sites and apps to customers.

[im-yf-promo]

While we acknowledge the potential of FSLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 10 Best Car Stocks to Buy in 2026 and 10 Best AI Stocks to Buy for the Next 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.